“So they’re suggesting that perhaps the IL-17 pathway might be more effective in the preclinical phase,” Dr. Pope said. “And perhaps that’s why they don’t work in patients with established rheumatoid arthritis—because the window of opportunity is already passed.”
Thomas R. Collins is a freelance writer living in South Florida.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
References
- Bialas AR, Presumey J, Das A, et al. Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature. 2017 Jun 22;546(7659):539–543.
- Takahashi T, Asano Y, Sugawara K, et al. Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma. J Exp Med. 2017 Apr 3;214(4):1129–1151.
- Corciulo C, Lendhey M, Wilder T, et al. Endogenous adenosine maintains cartilage homeostasis and exogenous adenosine inhibits osteoarthritis progression. Nat Commun. 2017 May 11;8:15019.
- Pfeifle R, Rothe T, Ipseiz N, et al. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat Immunol. 2017 Jan;18(1):104–113.
